Heart attack

May 11, 2019

Vasoactive Intestinal Polypeptide (PHM27/VIP)-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Vasoactive Intestinal Polypeptide (PHM27/VIP), , a peptide hormone consisting of 28 amino acids that promotes contractility, vasodilation, glycogenosis, arterial blood pressure and others, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 11/May/2019, 6.55 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]
May 10, 2019

Atrasentan-based therapy for Cardiac repair and myocardial infarction: Atrasentan, a drug used in the treatment of cancer,  pulmonary hypertension and others, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 10/May/2019,  11.48 pm

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
May 8, 2019

Canagliflozin-based therapy for Cardiac repair and myocardial infarction: Canagliflozin (trade name: Invokana, Sulisent, Prominad, others), a sodium-glucose cotransporter 2 inhibitor used in the treatment of TIIDM, increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up-regulation of its target gene, 8/May/2019,  6.59 am

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, […]
May 7, 2019

Liraglutide-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Liraglutide (Brand name: Victoza, Saxenda, others), a GLP-1 receptor agonist used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 7/May/2019, 6.36 am

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was […]